The health care industry has used AI for decades, but the rise of generative AI raises questions about how to regulate the technology.

Proposed AI legislation in California may have big implications in health care.

What should public life sciences companies should know about expansive new theories of liability in two insider trading cases?

Federal agencies and lawmakers in several states are attempting to rewrite the rulebook for private investment in health care in the U.S.

The Supreme Court should reverse a decision on statutory patent term guarantees for Patent Office delays, Orrick’s Irena Royzman and Lauren Drake say.

Reverse mergers have helped biotech companies access public markets, but recent SEC positions are threatening that path to going public.